Cantor Fitzgerald Reiterates Overweight on Reata Pharmaceuticals, Raises Price Target to $314

Cantor Fitzgerald reiterates Reata Pharmaceuticals (NASDAQ:RETA) with a Overweight and raises the price target from $250 to $314.

Benzinga · 11/20/2019 12:27

Cantor Fitzgerald reiterates Reata Pharmaceuticals (NASDAQ:RETA) with a Overweight and raises the price target from $250 to $314.